Demographic and functional characteristics of study subjects
| Visit A (n = 20)† | Visit B (n = 20)† | |
|---|---|---|
| *Age and lung function results are expressed as mean (range). | ||
| †Visit A: premedication with inhaled salbutamol 400 µg pMDI. Visit B: premedication with inhaled salbutamol 400 µg pMDI + nebulised salbutamol 1500 µg. | ||
| Age (years)* | 44 (23–82) | 44 (23–82) |
| Sex (F/M) | 11/9 | 11/9 |
| Smoking habit | 6/20 | 6/20 |
| Pre-bronchodilator FEV1 (ml)* | 2337 (1030–3670) | 2306 (1120–3610) |
| Pre-bronchodilator FEV1 (% pred)* | 73 (38–132) | 73 (44–136) |
| Post-bronchodilator FEV1 (ml)* | 2554 (1130–3500) | 2651 (1170–3680) |
| Reversibility (%)* | 13 (−15–59) | 17 (−2–70) |
| Post-bronchodilator FEV1 (% pred)* | 80 (40–143) | 82 (40–142) |
| Post-bronchodilator FEV1 ⩾65% | 14/20 | 16/20 |
| Post-bronchodilator FEV1 <65% | 6/20 | 4/20 |